INSP
$55.15
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers...
Recent News
A Look At Inspire Medical Systems (INSP) Valuation After Mixed Q4 Earnings Beat And Reduced 2026 Revenue Guidance
Inspire Medical Systems (INSP) is back in focus after fourth quarter 2025 results paired stronger than expected adjusted earnings per share of US$1.65 with reduced 2026 revenue guidance and higher earnings guidance. See our latest analysis for Inspire Medical Systems. At a share price of US$58.87, Inspire Medical Systems has a 90 day share price return of 49.03% decline and a 1 year total shareholder return of 64.66% decline, pointing to fading momentum despite the recent earnings beat and...
Why Is Inspire (INSP) Down 2.4% Since Last Earnings Report?
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
1 Cash-Heavy Stock to Research Further and 2 That Underwhelm
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Inspire Medical Systems (INSP): Buy, Sell, or Hold Post Q4 Earnings?
Shareholders of Inspire Medical Systems would probably like to forget the past six months even happened. The stock dropped 22.7% and now trades at $62.98. This may have investors wondering how to approach the situation.
Should You Buy, Hold or Sell Tempus AI Stock Heading Into 2026?
TEM eyes 2026 growth by scaling diagnostics, MRD testing and AI-driven clinical apps as revenues surge 83%, though valuation concerns temper the outlook.